Wegovy launches in Australia The manufacturer assured GPs supply planning has been its priority amid critical Ozempic shortages, but concerns remain over Wegovy’s availability.
Mounjaro expanded to include weight management The TGA has approved tirzepatide for the treatment of overweight and obesity for those with comorbidities, via private prescription.
‘I couldn’t walk’: GP’s personal story of vitamin B6 toxicity Found in listed medicines, energy drinks, cereals and weight loss shakes, some people are consuming more than 50x the recommended daily intake.
Have the benefits of statins been overstated? Researcher Paula Byrne writes on what she and her colleagues learned from a meta-analysis of 21 clinical trials involving 140,000 patients.
Mounjaro approved to treat sleep apnoea Sleep health experts welcome the approval of the first medicine indicated to treat obstructive sleep apnoea in patients with obesity.
Study compares Mounjaro to Wegovy for weight loss A new clinical trial, sponsored by the manufacturer, found Mounjaro led to greater weight loss, but GPs warn of its ‘risks of biases’.
What is Ryeqo? While the medicine has already been available in Australia since 2022, it was recently approved for the treatment of endometriosis.
Warning after melatonin sales suspended As an online retailer pauses melatonin supplement sales in Australia, it prompts an expert to call for a rethink on how children’s sleep issues are approached.
Concerns over growing misuse of Rikodeine cough medicine The addictive cough suppressant is popular among young people, more potent than codeine, and poses a serious risk of harm.
Should Australia be worried about HMPV? As cases of human metapneumovirus surge overseas, what do Australian GPs need to know when concerned patients walk through their door?